Company profile: Iterum Therapeutics
1.1 - Company Overview
Company description
- Provider of clinical-stage anti-infectives targeting multi-drug resistant pathogens. Offers sulopenem, an oral and IV penem antibiotic with broad-spectrum activity against multi-drug resistant gram-negative infections in hospital and community settings.
Products and services
- Sulopenem IV: Intravenous penem antibiotic delivering broad-spectrum activity against multi-drug resistant gram-negative infections in hospital settings, engineered for serious and life-threatening diseases
- Sulopenem Oral: Oral penem antibiotic with broad-spectrum activity targeting multi-drug resistant gram-negative infections in community settings, clinical-stage product aimed at significantly improving lives around the world
- Differentiated Anti-infective Development: Clinical-stage engineering of significantly differentiated anti-infective products to combat the global crisis of MDR pathogens causing serious and life-threatening diseases
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Iterum Therapeutics
HandyLab
HQ: United States
Website
- Description: Provider of medical technology developing and manufacturing molecular diagnostic assays and automation platforms. Using patented real-time microfluidic PCR technology, its proprietary platform reduces the time, cost, and complexity of testing while improving result quality, and is positioned to decentralize.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full HandyLab company profile →
Calimmune
HQ: United States
Website
- Description: Provider of clinical-stage gene therapies, including a lead gene-based therapeutic candidate engineered to control HIV infection and protect individuals with HIV from progressing to AIDS. The therapy is currently being evaluated in Phase I/II studies. Cal-1 is designed to reduce production of CCR5, a protein.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Calimmune company profile →
Biocure Technology
HQ: Canada
Website
- Description: Provider of biosimilars and CAR-T cell pharmaceutical products.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Biocure Technology company profile →
Biophytis
HQ: France
Website
- Description: Provider of clinical-stage therapeutics for metabolic and age-related diseases, developing orally administered small molecules including Ruvembri for sarcopenia via MAS receptor activation to stimulate respiratory and motor functions, BIO101 for neuromuscular diseases (sarcopenia, DMD) and in a phase 2 obesity study with GLP-1 receptor agonists, and Macuneos (BIO201) for retinal diseases (dry AMD, Stargardt).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Biophytis company profile →
Now Diagnostics
HQ: United States
Website
- Description: Provider of rapid, single-drop-of-blood diagnostic tests delivering results within minutes, including ADEXUSDx assays for COVID-19 antibodies, hCG for early pregnancy, syphilis antibodies, elevated acetaminophen, H-FABP for myocardial damage, and methanol detection in blood, plasma, or serum.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Now Diagnostics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Iterum Therapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Iterum Therapeutics
2.2 - Growth funds investing in similar companies to Iterum Therapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Iterum Therapeutics
4.2 - Public trading comparable groups for Iterum Therapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →